Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited announced that it has received a Drug Registration Certificate from the National Medical Products Administration for its Sildenafil Citrate Orodispersible Tablets, used to treat erectile dysfunction. This approval marks a significant milestone for the company, potentially enhancing its market position given the substantial sales of sildenafil-related preparations in China’s public medical institutions, which amounted to approximately RMB 5.2 billion in 2024.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production and sale of prescription drugs. The company focuses on developing chemical-based medications and has a significant presence in the domestic pharmaceutical market.
Average Trading Volume: 8,154,323
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.64B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.